China Diabetes Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

The China Diabetes Devices Market size is estimated at USD 7.43 billion in 2024, and is expected to reach USD 9.33 billion by 2029, growing at a CAGR of 4.66% during the forecast period (2024-2029).

According to WHO in January 2020 COVID -19 deaths, there are 20% of people with diabetes and diabetes-related diseases happened in China. Nearly one in ten COVID-19 patients have diabetes in China. Diabetes is associated with a higher risk of severe illness and death. The present study suggested that targeted early intervention is needed in COVID-19 patients with diabetes. According to a study conducted by Peking University, (Beijing China) the intensive care unit (ICU) cases had a roughly three-fold greater frequency of diabetes than non-ICU individuals. Various research produced different findings about the prevalence of diabetes. Almost 60% of those with diabetes experienced food or medication shortages during the quarantine period, which was much higher than those without diabetes. Importantly, respondents who experienced medication shortages reported a 63% higher COVID-19 infection rate.

In 2021, Type 1 diabetes patients accounted for 9.84% of the total diabetes population in China. In China, due to lifestyle and food habits, blood glucose fluctuations among insulin users are frequent from time to time, and self-monitoring of blood glucose fails to accurately reflect the blood glucose profile because it only represents the glucose concentration at a specific time point. Thus, a trend has been observed in the demand for the Diabetes Devices in China.

China Diabetes Devices Market Trends

Monitoring Devices Market is growing with the highest CAGR in forecast period

Patients with type-1 diabetes (T1D) must maintain healthy lifestyle conditions, which depend on a person's personality traits, social interactions, socioeconomic circumstances, and environmental living factors. Continuous glucose monitoring (CGM) with multiple daily injections (MDI) reduced non severe and severe hypoglycemia in people with T1 diabetes prone to this adverse event. Patients with type-1 diabetes at high risk of hypoglycemia could control their blood sugar levels even amid the harsh living circumstances imposed by the COVID-19 pandemic crisis' severe lockdown, thanks to standalone continuous glucose monitoring. A slight improvement in geometric markers, particularly those connected to glucose exposure, was linked to the lockdown time. The Spanish hospitals ordered CGM devices to limit staff contact with many diabetic patients infected with COVID-19. Blood sugar meters (BGMs) and strips monitor a person's blood sugar level at the precise moment of checking. They insert a test strip into a meter, use a lancing tool to prick their fingers to draw blood, and then place a tiny drop onto the test strip.

Treatment for viral infections in diabetics might be challenging because of BG level variations. With RT-CGM, monitoring BG trends and stopping drastic fluctuations in glucose levels before they cause problems is possible. The Dexcom G4 Platinum CGM system's ability to watch from up to 6.0 m reduced the requirement for medical personnel to enter the isolation room. These factors are driving the monitoring device market in China. The number of generic manufacturers in the nation is significantly rising, and type-1 diabetes patients are increasingly favoring cost-effective treatments, boosting the expansion of the market under study.

Increasing Type -1 Diabetes Population in China

According to estimates, 1 in 10 Chinese citizens have diabetes. During the 21st Century, millions of new cases of diabetes are occurring each year. However, a precise statistic for diabetes in China is difficult to calculate because many cases remain undetected. China is believed to have surpassed India as the country with the most significant diabetes population in the world. Diabetes is most prevalent in China's cities, where economic growth is accelerating, and traditional dietary patterns are rapidly eroding. According to China health experts, the fundamental causes of this diabetes number spike include urbanization, improving living standards, and an aging population. According to the National Health Commission, China has made steps to reduce diabetic and high blood pressure patients' medical expenses by reimbursing outpatients for more than half of their medication costs (NHC). According to a national metabolic disease clinical research center, more hospitals in China will establish National Metabolic Management Centers (MMC) as part of their exploration of a new model of diabetes treatment. According to the National Health Commission, China Statistics, MMCs have provided services for more than 200,000 patients over the last two years.

As a result, the diabetes care market in China is predicted to expand gradually in the coming years.

China Diabetes Devices Industry Overview

The new technologies in diabetes devices, like continuous glucose monitoring, have increased the market for monitoring devices. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, are paving the way for automated insulin delivery. The acquisition has sent Dexcom ahead on its way in the race to create an artificial pancreas system, rather than merely offering a boost to the continuous glucose monitoring device market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support